Cetiner Mustafa, Eskut Neslihan, Akdag Gonul, Arikan Fatma Akkoyun, Guler Merve, Kabay Sibel Canbaz
Department of Neurology, Kutahya Health Sciences University Faculty of Medicine, Kutahya, Türkiye.
Department of Neurology, Health Science University Bozyaka Education and Research Hospital, Izmir, Türkiye.
Sisli Etfal Hastan Tip Bul. 2023 Sep 29;57(3):359-366. doi: 10.14744/SEMB.2023.51437. eCollection 2023.
This study aimed to investigate the clinical data of patients with acute ischemic stroke who received low-dose intravenous (IV) thrombolytic therapy (0.9 mg/kg; maximum 50 mg) for various reasons, compare the obtained results with those of patients who received standard-dose thrombolytic therapy, and discuss them in light of the literature.
Patients who received IV thrombolytic therapy within 4.5 h of symptom onset between January 2015 and June 2018 were retrospectively reviewed. Patients were divided into the low-dose group (0.9 mg/kg; max. 50 mg) and the standard-dose group (0.9 mg/kg; max 90 mg) according to the thrombolytic therapy dose, after which demographic data and clinical results were analyzed.
A total of 109 patients receiving thrombolytic therapy (19 patients in the low-dose group and 90 patients in the standard-dose group) were included in the study. There was no significant difference between the two groups in terms of good outcome rates (47.4% vs. 52.2%). There was no statistically significant difference in terms of symptomatic and asymptomatic intracerebral hemorrhage rates.
Our study showed similar efficacy and safety for low-dose IV thrombolytic therapy compared with standard-dose IV thrombolytic therapy administered within 4.5 h of symptom onset in patients with acute ischemic stroke.
本研究旨在调查因各种原因接受低剂量静脉溶栓治疗（0.9mg/kg；最大剂量50mg）的急性缺血性脑卒中患者的临床资料，将所得结果与接受标准剂量溶栓治疗的患者进行比较，并结合文献进行讨论。
回顾性分析2015年1月至2018年6月期间在症状发作4.5小时内接受静脉溶栓治疗的患者。根据溶栓治疗剂量将患者分为低剂量组（0.9mg/kg；最大剂量50mg）和标准剂量组（0.9mg/kg；最大剂量90mg），然后分析人口统计学数据和临床结果。
本研究共纳入109例接受溶栓治疗的患者（低剂量组19例，标准剂量组90例）。两组的良好预后率无显著差异（47.4%对52.2%）。有症状和无症状脑出血率方面无统计学显著差异。
我们的研究表明，与在急性缺血性脑卒中患者症状发作4.5小时内给予的标准剂量静脉溶栓治疗相比，低剂量静脉溶栓治疗具有相似的疗效和安全性。
